These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28961375)

  • 1. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
    Lücking U; Scholz A; Lienau P; Siemeister G; Kosemund D; Bohlmann R; Briem H; Terebesi I; Meyer K; Prelle K; Denner K; Bömer U; Schäfer M; Eis K; Valencia R; Ince S; von Nussbaum F; Mumberg D; Ziegelbauer K; Klebl B; Choidas A; Nussbaumer P; Baumann M; Schultz-Fademrecht C; Rühter G; Eickhoff J; Brands M
    ChemMedChem; 2017 Nov; 12(21):1776-1793. PubMed ID: 28961375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
    Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
    J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
    Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
    Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
    Barlaam B; Casella R; Cidado J; Cook C; De Savi C; Dishington A; Donald CS; Drew L; Ferguson AD; Ferguson D; Glossop S; Grebe T; Gu C; Hande S; Hawkins J; Hird AW; Holmes J; Horstick J; Jiang Y; Lamb ML; McGuire TM; Moore JE; O'Connell N; Pike A; Pike KG; Proia T; Roberts B; San Martin M; Sarkar U; Shao W; Stead D; Sumner N; Thakur K; Vasbinder MM; Varnes JG; Wang J; Wang L; Wu D; Wu L; Yang B; Yao T
    J Med Chem; 2020 Dec; 63(24):15564-15590. PubMed ID: 33306391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death.
    Ruff JP; Kretz AL; Kornmann M; Henne-Bruns D; Lemke J; Traub B
    Anticancer Res; 2021 Dec; 41(12):5973-5985. PubMed ID: 34848451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
    Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
    Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models.
    Wang L; Hu C; Wang A; Chen C; Wu J; Jiang Z; Zou F; Yu K; Wu H; Liu J; Wang W; Wang Z; Wang B; Qi Z; Liu Q; Wang W; Li L; Ge J; Liu J; Liu Q
    Invest New Drugs; 2020 Oct; 38(5):1272-1281. PubMed ID: 31872348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
    Sonawane YA; Taylor MA; Napoleon JV; Rana S; Contreras JI; Natarajan A
    J Med Chem; 2016 Oct; 59(19):8667-8684. PubMed ID: 27171036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Han X; Song N; Saidahmatov A; Wang P; Wang Y; Hu X; Kan W; Zhu W; Gao L; Zeng M; Wang Y; Li C; Li J; Liu H; Zhou Y; Wang J
    J Med Chem; 2021 Oct; 64(19):14647-14663. PubMed ID: 34477384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.
    Phillipson LJ; Segal DH; Nero TL; Parker MW; Wan SS; de Silva M; Guthridge MA; Wei AH; Burns CJ
    Bioorg Med Chem; 2015 Oct; 23(19):6280-96. PubMed ID: 26349627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
    Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T
    J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
    Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
    Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK9 inhibitors in acute myeloid leukemia.
    Boffo S; Damato A; Alfano L; Giordano A
    J Exp Clin Cancer Res; 2018 Feb; 37(1):36. PubMed ID: 29471852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
    Li Y; Guo Q; Zhang C; Huang Z; Wang T; Wang X; Wang X; Xu G; Liu Y; Yang S; Fan Y; Xiang R
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3231-3237. PubMed ID: 28651979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halogen bonds form the basis for selective P-TEFb inhibition by DRB.
    Baumli S; Endicott JA; Johnson LN
    Chem Biol; 2010 Sep; 17(9):931-6. PubMed ID: 20851342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development.
    Liu Y; Xu Z; Hu L; Xia L; Li Q; Zhou W; Chen Y; Li W; Jiang W; Zhu X; Gao X; Xia Y; Zhu Z; Chen S; Ding CZ
    Bioorg Med Chem Lett; 2024 Nov; 112():129941. PubMed ID: 39222890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
    Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R
    Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
    Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
    Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
    Štětková M; Growková K; Fojtík P; Valčíková B; Palušová V; Verlande A; Jorda R; Kryštof V; Hejret V; Alexiou P; Rotrekl V; Uldrijan S
    Cell Death Dis; 2020 Sep; 11(9):754. PubMed ID: 32934219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.